RAMP TESTS FOR CARDIOVASCULAR DIAGNOSIS
Cardiovascular disease claims the lives of 17.9 million people each year and is the leading cause of death in men and women of all races. Point-of-care heart testing can improve the efficiency of patient care by reducing length of stay and health care costs. At MEDICEXPERT, we are committed to delivering lab-quality results to you within minutes, because every test counts.
RAMP TESTS FOR CARDIOVASCULAR DIAGNOSIS
Cardiovascular disease claims the lives of 17.9 million people each year and is the leading cause of death in men and women of all races. Point-of-care heart testing can improve the efficiency of patient care by reducing length of stay and health care costs. At MEDICEXPERT, we are committed to delivering lab-quality results to you within minutes, because every test counts.
THE TESTS
REF : MEC RAMP DDIMER
THE BIOMARKER OF VENOUS THROMBOEMBOLIA
MEDICEXPERT provides a D-dimer test which quantitatively measures D-dimer in whole blood EDTA. D-dimer is a valuable diagnostic marker that provides a rapid and economical means of helping to rule out venous thromboembolism, including thromboembolic events such as deep vein thrombosis and pulmonary embolism. Our RAMP D-dimer assay provides lab-grade results in less than 15 minutes without the need for centrifugation.
D-dimer is a small biomarker for the activation of coagulation and is present in the blood when a blood clot is broken down. We offer you this quantitative whole blood D-dimer immunoassay, with our proprietary RAMP technology that assesses D-dimer levels in patients around the world in approximately 15 minutes. Find out how this product will help you meet the challenges facing laboratories and physicians, finding the right D-dimer test for your needs.
THE CHALLENGE > VENOUS THROMBOEMBOLISMS ARE DIFFICULT TO DIAGNOSE
◉ Deep vein thrombosis (DVT) and pulmonary embolism (PE) are difficult diagnostic conditions that come at a high cost if not recognized and treated promptly.
◉ Accurate diagnosis of DVT and PE remains a problem and with inadequate testing risky and expensive imaging and treatments can be performed unnecessarily.
◉ DVT and PE present like many other medical problems, but emergency physicians have no time to waste and the majority of PE-related deaths occur within the first hour.
THE SOLUTION > THE D-DIMER RAMP TEST
◉ Research shows that the degradation product of D-dimer fibrin, in general, is a valuable diagnostic marker used to help rule out venous thromboembolism (VTE), including thromboembolic events such as deep vein thrombosis (DVT) and pulmonary embolism (PE).
◉ The D-DIMER RAMP, unlike traditional D-dimer assays, uses EDTA whole blood directly and samples do not require centrifugation and speed up processing time .
◉ The D-DIMER RAMP is relatively inexpensive and provides laboratory-grade quantitative results in approximately 15 minutes .
THE PRINCIPLES
◉ Quantitative fluorescent immunoassay
◉ Sample : 75 µL EDTA whole blood
◉ Result time : ~ 15 minutes
◉ Single-use barcode test cartridge defines lot-specific calibration
◉ Exclusive RAMP buffer improves performance
◉ A calibrated transfer device is supplied with each kit
◉ The RAMP report corrects the sources of analytical variability
REF : MEC RAMP NTPROBNP
THE STANDARD BIOMARKER FOR HEART FAILURE (CI)
MEDICEXPERT provides rapid and accurate diagnosis and assessment of congestive heart failure in approximately 15 minutes. RAMP NT-proBNP helps in risk stratification of patients with heart failure and offers diagnostic accuracy comparable to that of Roche Elecsys proBNP. Find out why people are switching from BNP to NT-proBNP as the gold standard biomarker test for heart failure.
MEDICEXPERT offers an FDA-approved NT-proBNP whole blood immunoassay with our proprietary RAMP technology that detects levels of the N-terminal prohormone of brain natriuretic peptide in patients with congestive heart failure worldwide. Find out how this product will help your doctors and patients where a traditional BNP test cannot.
THE CHALLENGE > THE MANAGEMENT OF PATIENTS WITH HEART FAILURE
◉ 1 in 4 patients will be readmitted within 30 days of discharge, the highest readmission rate of any discharge diagnosis
◉ 1 in 5 people diagnosed with heart failure die within the first year and around half of people who develop heart failure die within 5 years of diagnosis
◉ Heart failure often has nonspecific symptoms and is often mistaken for pneumonia or COPD
◉ Heart attacks and coronary artery disease are two of the most expensive conditions to treat.
THE SOLUTION > THE NT-proBNP RAMP TEST
◉ The test provides fast and accurate diagnosis and evaluation of congestive heart failure.
◉ NT-proBNP is approximately 5 times more stable as a biomarker than BNP
◉ Better accuracy in patients with mild heart failure, as NT-proBNP levels are 2-10 times higher
◉ Standardized on the Roche Elecsys laboratory analyzer
THE PRINCIPLES
◉ Quantitative fluorescent immunoassay
◉ Sample: 75 µL of EDTA whole blood
◉ Result time: ~ 15 minutes
◉ Single-use barcode test cartridge defines lot-specific calibration
◉ Exclusive RAMP buffer improves performance
◉ A calibrated transfer device is supplied with each kit
◉ The RAMP report corrects the sources of analytical variability
REF : MEC RAMP TROPONIN
BDEFINITIVE MARKER OF ACUTE MYOCARDIAL INFARCT (AMI)
MEDICEXPERT provides a full range of quantitative tests to aid in the accurate diagnosis of AMI. RAMP cardiovascular tests are designed to be easy to use and provide lab-quality results you can count on in an emergency. Learn more about how our self-calibrated instruments can help improve the operational efficiency of your facility.
THE CHALLENGE > WHEN IAM'S EARLY RECOGNITION IS KEY
◉ An estimated 17.9 million people died from cardiovascular disease in 2016, or 31% of all deaths worldwide
◉ There are 32.4 million myocardial infarctions and strokes in the world every year
◉ The sensitivity of ECGs for MI is low (28% -54%)
◉ One third of patients with MI do not have chest pain but rather non-specific symptoms such as fatigue, nausea, dizziness
THE SOLUTION > THE RAMP TROPONIN I TEST (TNI)
◉ Cardiac troponin is the gold standard test for myocardial infarction and is usually the first test ordered for patients with chest pain
◉ Measurements of cardiac troponin I may improve the diagnosis and treatment of myocardial infarction (MI)
◉ With RAMP Troponin I, healthcare professionals can obtain a quantitative measurement of cardiac troponin I from 75 µL of blood without the need for centrifugation
◉ RAMP assays are single-use, single-use quantitative assays that deliver fast, accurate, lab-quality results within minutes
THE PRINCIPLES
◉ Quantitative fluorescent immunoassay
◉ Sample: 75 µL of EDTA whole blood
◉ Result time: ~ 19 minutes
◉ Single-use barcode test cartridge defines lot-specific calibration
◉ Exclusive RAMP buffer improves performance
◉ A calibrated transfer device is supplied with each kit
◉ The RAMP report corrects the sources of analytical variability
REF : MEC RAMP MYOGLOBIN
BIOMARKER OF ACUTE MYOCARDIAL INFARCTION (AMI)
Myoglobin is a cytoplasmic protein of striated muscles (skeletal muscle and myocardium). The serum level of myoglobin increases approximately 2 hours after a myocardial infarction, which makes it the earliest biomarker of this pathology. The concentration reaches its maximum value between 4 to 12 hours. The determination of myoglobin in serum is therefore used for the early diagnosis of acute myocardial infarction, but also to detect an early recurrence of infarction.
MEDICEXPERT offers you the RAMP Myoglobin test which provides laboratory quality quantitative results in less than 10 minutes without the need for centrifugation.
THE PRINCIPLES
◉ Quantitative fluorescent immunoassay
◉ Sample: 75 µL of EDTA whole blood
◉ Result time: ~ 10 minutes
◉ Functional range: 0 - 400.0 ng/mL
◉ Single-use test cassette with barcode that automatically sets lot-specific calibration
◉ Exclusive RAMP buffer improves performance
◉ A calibrated transfer device is supplied with each kit
◉ RAMP report corrects sources of analytical variability
REF : MEC RAMP CK-MB
BIOMARKER OF ACUTE MYOCARDIAL INFARCTION (AMI)
CK-MB is an enzyme that catalyzes the transformation of ADP into ATP during intensive efforts such as a myocardial infarction. It is therefore a useful biomarker in the diagnosis of an AMI. Its increase becomes detectable within 3 to 12 hours following a myocardial infarction, with a peak around the 24th hour. The CK-MB assay is used in the early diagnosis of myocardial infarction to estimate the start time of the infarction, its size and extent, and to diagnose recurrence of ischemia or infarction.
MEDICEXPERT offers you the RAMP CK-MB test which provides laboratory quality quantitative results in less than 12 minutes without the need for centrifugation.
THE PRINCIPLES
◉ Quantitative fluorescent immunoassay
◉ Sample: 75 µL of EDTA whole blood
◉ Result time: ~ 12 minutes
◉ Functional range: 0 - 80.0 ng/mL
◉ Single-use test cassette with barcode that automatically sets lot-specific calibration
◉ Exclusive RAMP buffer improves performance
◉ A calibrated transfer device is supplied with each kit
◉ RAMP report corrects sources of analytical variability
REF : MEC RAMP CTRLCARD
MEDICEXPERT provides two levels of cardiac controls for use as quality control material tested for RAMP Troponin, RAMP NT-proBNP, RAMP Myoglobin, RAMP CK-MB and RAMP D-dimer assays.